<DOC>
	<DOC>NCT02185794</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and antiviral activity of GS-9857 alone or with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) in adults with genotypes 1, 2, 3, or 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose to monitor for persistence of viral mutations.</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Chronic genotype 14 HCV infection For Cohorts 19, HCV RNA â‰¥ 100,000 IU/mL at screening (no HCV RNA restriction for Cohort 10) Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female or male with pregnant female partner Presence of cirrhosis Prior exposure to approved or experimental HCV Protease Inhibitors Coinfection with HIV or hepatitis B virus (HBV) Current or prior history of clinical hepatic decompensation Chronic use of systemic immunosuppressive agents History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HCV genotype 1 (GT-1)</keyword>
	<keyword>HCV genotype 2 (GT-2)</keyword>
	<keyword>HCV genotype 3 (GT-3)</keyword>
	<keyword>HCV genotype 4 (GT-4)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Open Label</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis, Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
</DOC>